$1.58 Billion is the total value of Boxer Capital, LLC's 76 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 10.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | Mirati Therapeutics Inc | $134,260,000 | -18.4% | 2,000,000 | 0.0% | 8.50% | +0.6% | |
| CYTK | Cytokinetics Inc | $82,509,000 | +6.7% | 2,100,000 | 0.0% | 5.23% | +31.5% | |
| BGNE | BeiGene Ltdsponsored adr | $80,925,000 | -14.2% | 500,000 | 0.0% | 5.12% | +5.7% | |
| RVMD | Revolution Medicines Inc | $67,908,000 | -23.6% | 3,484,264 | 0.0% | 4.30% | -5.8% | |
| APLS | Apellis Pharmaceuticals Inc | $58,953,000 | -11.0% | 1,303,700 | 0.0% | 3.73% | +9.7% | |
| SWTX | Springworks Therapeutics Inc | $51,109,000 | -56.4% | 2,075,905 | 0.0% | 3.24% | -46.2% | |
| PMVP | PMV Pharmaceuticals Inc | $49,856,000 | -31.6% | 3,498,636 | 0.0% | 3.16% | -15.7% | |
| RXDX | Prometheus Biosciences Inc | $48,386,000 | -25.2% | 1,714,000 | 0.0% | 3.06% | -7.9% | |
| Tyra Biosciences Inc | $46,106,000 | -33.2% | 6,448,359 | 0.0% | 2.92% | -17.7% | ||
| RLAY | Relay Therapeutics Inc | $44,708,000 | -44.0% | 2,669,132 | 0.0% | 2.83% | -31.0% | |
| ITOS | Sell | iTeos Therapeutics Inc | $44,374,000 | -56.8% | 2,154,058 | -32.5% | 2.81% | -46.8% |
| MRUS | Merus N V | $43,016,000 | -14.4% | 1,900,000 | 0.0% | 2.72% | +5.5% | |
| TPTX | Buy | Turning Point Therapeutics I | $42,949,000 | +299.9% | 570,745 | +42.7% | 2.72% | +392.8% |
| Amylyx Pharmaceuticals Inc | $42,372,000 | +49.9% | 2,200,000 | 0.0% | 2.68% | +84.7% | ||
| RETA | Reata Pharmaceuticals Inccl a | $37,653,000 | -7.2% | 1,239,000 | 0.0% | 2.38% | +14.3% | |
| XBI | Sell | SPDR SER TRs&p biotech | $37,135,000 | -41.0% | 500,000 | -28.6% | 2.35% | -27.3% |
| RCUS | Arcus Biosciences Inc | $36,292,000 | -19.7% | 1,432,200 | 0.0% | 2.30% | -1.0% | |
| SAGE | Sage Therapeutics Inc | $35,336,000 | -2.4% | 1,094,000 | 0.0% | 2.24% | +20.3% | |
| Tango Therapeutics Inc | $31,129,000 | -40.2% | 6,871,642 | 0.0% | 1.97% | -26.3% | ||
| IDYA | Ideaya Biosciences Inc | $30,399,000 | +23.3% | 2,202,812 | 0.0% | 1.92% | +51.9% | |
| BLU | Bellus Health Inc New | $29,568,000 | +34.3% | 3,200,000 | 0.0% | 1.87% | +65.5% | |
| ANAB | AnaptysBio Inc | $26,390,000 | -17.9% | 1,300,000 | 0.0% | 1.67% | +1.1% | |
| BPMC | Blueprint Medicines Corp | $25,627,000 | -20.9% | 507,374 | 0.0% | 1.62% | -2.6% | |
| FOLD | Amicus Therapeutics Inc | $24,971,000 | +13.4% | 2,325,000 | 0.0% | 1.58% | +39.8% | |
| KNTE | Kinnate Biopharma Inc | $23,298,000 | +12.0% | 1,847,559 | 0.0% | 1.48% | +38.1% | |
| IOVA | Iovance Biotherapeutics Inc | $21,364,000 | -33.7% | 1,935,133 | 0.0% | 1.35% | -18.3% | |
| DAWN | Day One Biopharmaceuticals | $21,300,000 | +80.4% | 1,189,943 | 0.0% | 1.35% | +122.2% | |
| GOSS | Gossamer Bio Inc | $20,610,000 | -3.6% | 2,462,358 | 0.0% | 1.30% | +18.7% | |
| RCKT | Rocket Pharmaceuticals Inc | $20,173,000 | -13.2% | 1,466,051 | 0.0% | 1.28% | +6.9% | |
| XENE | Xenon Pharmaceuticals Inc | $18,252,000 | -0.5% | 600,000 | 0.0% | 1.16% | +22.6% | |
| ACAD | Acadia Pharmaceuticals Inc | $17,809,000 | -41.8% | 1,263,930 | 0.0% | 1.13% | -28.2% | |
| PNT | Point Biopharma Global Inc | $17,025,000 | -14.6% | 2,500,000 | 0.0% | 1.08% | +5.3% | |
| Nuvalent Inc | $16,410,000 | -2.4% | 1,210,192 | 0.0% | 1.04% | +20.3% | ||
| RNA | Avidity Biosciences Inc | $16,293,000 | -21.3% | 1,121,327 | 0.0% | 1.03% | -3.0% | |
| NRIX | Nurix Therapeutics Inc | $15,519,000 | -9.6% | 1,224,892 | 0.0% | 0.98% | +11.5% | |
| SRPT | New | Sarepta Therapeutics Inc | $14,992,000 | – | 200,000 | +100.0% | 0.95% | – |
| BMEA | Biomea Fusion Inc | $14,237,000 | +168.6% | 1,188,405 | 0.0% | 0.90% | +231.6% | |
| NUVB | Nuvation Bio Inc | $14,065,000 | -38.4% | 4,341,009 | 0.0% | 0.89% | -24.1% | |
| CGEM | Cullinan Oncology Inc | $13,770,000 | +22.4% | 1,074,082 | 0.0% | 0.87% | +50.9% | |
| MIST | Milestone Pharmaceuticals In | $13,769,000 | -4.2% | 2,238,861 | 0.0% | 0.87% | +18.0% | |
| FATE | Fate Therapeutics Inc | $12,390,000 | -36.1% | 500,000 | 0.0% | 0.78% | -21.2% | |
| GHRS | GH Research PLCordinary shares | $10,114,000 | -45.4% | 1,013,399 | 0.0% | 0.64% | -32.7% | |
| PRTA | Prothena Corp PLC | $8,145,000 | -25.8% | 300,000 | 0.0% | 0.52% | -8.5% | |
| AKRO | Akero Therapeutics Inc | $7,858,000 | -33.4% | 831,495 | 0.0% | 0.50% | -17.8% | |
| RAIN | Rain Therapeutics Inc | $6,533,000 | +9.7% | 1,175,000 | 0.0% | 0.41% | +35.3% | |
| ASND | New | Ascendis Pharma A/Ssponsored adr | $6,507,000 | – | 70,000 | +100.0% | 0.41% | – |
| NGM | NGM Biopharmaceuticals Inc | $6,410,000 | -15.9% | 500,000 | 0.0% | 0.41% | +3.6% | |
| CNTA | Centessa Pharmaceuticals PLCsponsored ads | $6,093,000 | -46.0% | 1,251,137 | 0.0% | 0.39% | -33.3% | |
| 2Seventy Bio Inc | $6,070,000 | -22.6% | 459,836 | 0.0% | 0.38% | -4.7% | ||
| DBVT | DBV Technologies S Asponsored adr | $5,443,000 | +60.4% | 2,134,598 | 0.0% | 0.34% | +98.3% | |
| BDTX | Black Diamond Therapeutics I | $4,957,000 | -11.2% | 2,014,858 | 0.0% | 0.31% | +9.4% | |
| BLSA | BCLS Acquisition Corp | $4,950,000 | +0.3% | 500,000 | 0.0% | 0.31% | +23.6% | |
| Theseus Pharmaceuticals Inc | $4,933,000 | -52.0% | 892,057 | 0.0% | 0.31% | -41.0% | ||
| PANA | Panacea Acquisition Corp II | $4,880,000 | +0.1% | 500,000 | 0.0% | 0.31% | +23.1% | |
| ORIC | Oric Pharmaceuticals Inc | $4,722,000 | -16.1% | 1,054,000 | 0.0% | 0.30% | +3.5% | |
| EQRx Inc | $4,690,000 | +13.6% | 1,000,000 | 0.0% | 0.30% | +40.1% | ||
| ETNB | New | 89Bio Inc | $4,508,000 | – | 1,400,000 | +100.0% | 0.29% | – |
| SELB | Selecta Biosciences Inc | $4,302,000 | +6.5% | 3,284,072 | 0.0% | 0.27% | +30.8% | |
| HSAQ | Health Sciences Acq Corp 2 | $3,984,000 | +0.5% | 400,000 | 0.0% | 0.25% | +23.5% | |
| BCEL | Atreca Inc | $3,942,000 | -43.5% | 2,202,333 | 0.0% | 0.25% | -30.4% | |
| COGT | New | Cogent Biosciences Inc | $3,834,000 | – | 425,000 | +100.0% | 0.24% | – |
| SLDB | Solid Biosciences Inc | $3,285,000 | -48.7% | 5,336,031 | 0.0% | 0.21% | -36.8% | |
| MREO | New | Mereo Biopharma Group PLCads | $2,520,000 | – | 2,250,000 | +100.0% | 0.16% | – |
| CDAK | Codiak Biosciences Inc | $2,448,000 | -54.1% | 850,065 | 0.0% | 0.16% | -43.4% | |
| EPIX | Essa Pharma Inc | $2,282,000 | -49.1% | 724,500 | 0.0% | 0.14% | -37.2% | |
| GMTX | Gemini Therapeutics Inc | $2,197,000 | +21.6% | 1,300,000 | 0.0% | 0.14% | +49.5% | |
| OMEG | Omega Alpha SPACcl a | $1,970,000 | +0.3% | 200,000 | 0.0% | 0.12% | +23.8% | |
| BCAB | BioAtla Inc | $1,956,000 | -43.3% | 686,347 | 0.0% | 0.12% | -29.9% | |
| ALGS | Aligos Therapeutics Inc | $1,847,000 | -43.7% | 1,526,048 | 0.0% | 0.12% | -30.8% | |
| MEIP | MEI Pharma Inc | $1,762,000 | +0.4% | 2,913,091 | 0.0% | 0.11% | +24.4% | |
| ELEV | Elevation Oncology Inc | $1,222,000 | -44.4% | 872,780 | 0.0% | 0.08% | -31.9% | |
| TARA | Protara Therapeutics Inc | $613,000 | -42.7% | 209,227 | 0.0% | 0.04% | -29.1% | |
| CABA | Cabaletta Bio Inc | $572,000 | -47.8% | 540,000 | 0.0% | 0.04% | -35.7% | |
| NUVBWS | Nuvation Bio Inc*w exp 07/07/202 | $75,000 | -63.1% | 266,666 | 0.0% | 0.01% | -50.0% | |
| Bellicum Pharmaceuticals Inc | $68,000 | -44.7% | 56,950 | 0.0% | 0.00% | -33.3% | ||
| Surrozen Incw exp 08/01/203 | $13,000 | -23.5% | 66,666 | 0.0% | 0.00% | 0.0% | ||
| GNCA | Exit | Genocea Biosciences Inc | $0 | – | -1,134,453 | -100.0% | -0.07% | – |
| ODT | Exit | Odonate Therapeutics Inc | $0 | – | -4,207,086 | -100.0% | -0.28% | – |
| RARE | Exit | Ultragenyx Pharmaceutical Inc | $0 | – | -200,000 | -100.0% | -0.75% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.